Forendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, today announces the appointment of David Colpman as a non-executive director to its Board of Directors.
Forendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, today announces the appointment of David Colpman as a non-executive director to its Board of Directors.
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2021 Optimum Strategic Communications All rights reserved.
8 Devonshire Square
Spitalfields
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
